Which funds bought or sold REGN in Q3 2026?
Regeneron Pharmaceuticals. 11 funds bought, 8 sold, out of 109 tracked funds that have filed for Q3 2026. Among active managers, the estimated net flow was −$195M.
Holdings as of Sep 30, 2026 (Q3 2026)13F deadline Nov 16, 2026 (45 days after quarter end)
- Citadel+$224M
- Two Sigma+$162M
- Marshall Wace+$145M
- Point72NEW+$94M
- Renaissance+$94M
- Northern Trust+$62M
- Bridgewater+$41M
- ExodusPointNEW+$29M
- TudorNEW+$29M
- MaverickNEW+$1M
- Goldman Sachs−$356M
- JPMorgan−$350M
- Invesco−$166M
- Man Group−$108M
- Susquehanna−$62M
- Adage−$46M
- Legal & General−$45M
- Southeastern−$9M
Top 10 each side. NEW = opened a position, OUT = sold the whole position.
Bought (11)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| Citadel Quant & multi-strategy | Added+512.3% | +$224M | $267M |
| Two Sigma Quant & multi-strategy | Added+32.5% | +$162M | $659M |
| Marshall Wace Quant & multi-strategy | Added+830.2% | +$145M | $162M |
| Point72 Quant & multi-strategy | New | +$94M | $94M |
| Renaissance Quant & multi-strategy | Added+83.7% | +$94M | $206M |
| Northern Trust Bank & broker | Added+8.9% | +$62M | $756M |
| Bridgewater Hedge fund | Added+106.4% | +$41M | $80M |
| ExodusPoint Quant & multi-strategy | New | +$29M | $29M |
| Tudor Hedge fund | New | +$29M | $29M |
| Maverick Hedge fund | New | +$1M | $1M |
| Pzena Value investor | New | +$310K | $310K |
Sold (8)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| Goldman Sachs Bank & broker | Trimmed-40.3% | −$356M | $526M |
| JPMorgan Bank & broker | Trimmed-12.4% | −$350M | $2.5B |
| Invesco Asset manager | Trimmed-5.6% | −$166M | $2.8B |
| Man Group Quant & multi-strategy | Trimmed-32.5% | −$108M | $224M |
| Susquehanna Quant & multi-strategy | Trimmed-45.3% | −$62M | $75M |
| Adage Hedge fund | Trimmed-72.9% | −$46M | $17M |
| Legal & General Asset manager | Trimmed-7.8% | −$45M | $531M |
| Southeastern Value investor | Trimmed-8% | −$9M | $106M |
Source: SEC EDGAR Form 13F-HR for each fund, holdings as of Sep 30, 2026. Shares only (options excluded). Estimated $ = change in shares × quarter-end price. Funds may have traded since. Methodology. Not investment advice.